Matched Sibling Donors Remain the Gold Standard for PTCy‑Based Allogeneic Stem Cell Transplantation

TheBrief**

Matched sibling donors remain the top choice for allogeneic hematopoietic cell transplantation (allo-HCT) using post-transplant cyclophosphamide (PTCy) , despite the continual improvement in other potential donor sources. Donor selection continues to impact survival, relapse risk, graft-versus-host disease (GVHD), infection risk and immune recovery time.PTCy has made it possible for more people to get transplants by improving the safety of haploidentical and unrelated donor procedures. Still, if a fully matched sibling donor is an option, that choice often remains the most straightforward and predictable route for many patients with blood cancers and bone marrow failure disorders.

Why It Matters**

The selection of donors is not just an important factor but one of the major factors that affect the transplantation procedure. The successfulness of the transplant is dependent on the compatibility of the immune system of the donor to the recipient. Compatibility is achieved through HLA matching, which ensures that the immune system will work together with the graft. Matched sibling donors offer a biological edge that no amount of medical intervention can replace. The presence of matching HLA markers between siblings results in a more predictable response by the graft. Patients may expect to suffer from a lesser incidence of severe acute GVHD; indeed, some patients also suffer from less probability of the occurrence of chronic GVHD. This is important since chronic GVHD involves damage not just to the skin but also the eyes, mouth, lungs, liver, joints and body as a whole. PTCy has revolutionized the area by decreasing the likelihood of GVHD and making a larger pool of donors eligible for transplants. By giving cyclophosphamide within days of transplantation, alloreactive T cells which promote GVHD can be selectively suppressed without compromising on reconstitution of the immune system. This technology has played an important role in bringing down the threshold of using haploidentical related donors and certain combinations of unrelated donors. From the patient’s perspective, this has meant getting access to transplants earlier than before. Despite having PTCy, the “starting point” is still important, and a good match between siblings is an ideal “starting point.” While PTCy may help eliminate complications due to the immune system, it does not negate all risks associated with mismatches. In instances where the donor and the recipient exhibit excellent HLA compatibility, it becomes easy to have fewer immune complications that arise. While speed is important, stability is too, and the matching between siblings may facilitate both of these qualities. There are many situations when people require allo-HCT within a relatively small period of time, including in cases where the person has gone into remission from acute leukemia. When there is a match between the patients and a sibling, this process becomes relatively fast as the process of identifying donors becomes faster compared to finding unrelated donors. At the same time, the quality of the match does not get worse. While GVHD needs to be prevented within the first 100 days, chronic GVHD may continue beyond that period, having a negative impact on the life of the person over many subsequent years. Some of the issues a person suffering from chronic GVHD may have to deal with include fatigue, pain, dry eyes, mouth sores, problems breathing, or constant infections. The use of a suitable donor decreases the probability of developing chronic GVHD and all related consequences. A matched sibling donor can also help with care planning after transplantation. While doctors will always base their decisions on individualized factors, the presence of a matched sibling donor reduces uncertainties. Infection prevention strategies, monitoring plans, and immunosuppressive tapering schedules can be more confidently planned. Patients may feel better knowing what to expect in terms of recovery, including when blood counts should be stabilized, when it becomes safe to resume certain activities, and for how long follow-up care might need to continue. The term “gold standard” carries broader implications than just clinical practice. The use of a matched sibling donor may entail fewer resource-intensive interventions needed to address complications arising during treatment. This could translate to fewer costly hospitalizations, fewer expensive immunosuppressive rescue treatments, and fewer treatments for chronic GVHD. These considerations impact the way payers and healthcare organizations make prior authorization and bundled payment decisions. On the other hand, not everybody has a matching sibling, and this fact highlights some inequalities in society. The size of families, adoption, family type, and genetic structure of the population affect the chances of obtaining the match. In particular, there may be a reduced possibility for individuals of different races and ethnic backgrounds to have a match in a registry for unrelated donors. Insurance and geography might prevent patients from visiting medical centers that specialize in complicated procedures with donors.

Who It Affects**

Discussion of blood cancer and bone marrow disorders is the topic of interest in this article. It should be noted that allo-HCT is regarded as a viable treatment modality in case of many leukemia patients, lymphomas, myelodysplastic syndromes, myeloproliferative neoplasms, and aplastic anemia, which is a bone marrow disorder without cancer. The presence of a matched sibling donor facilitates the transplant process and ensures minimal risks involved in the procedure. Even patients without matched siblings can get benefit from the use of PTCy. The role of haploid donors, mismatched donors, and cord blood cannot be overstated in terms of the expansion of treatment options for patients. However, PTCy has helped improve the safety aspect of each option. Nevertheless, infection surveillance might require to be more strict, and there could be more need for adjusting immunosuppression or support. This is not necessarily because the outcome will be less favorable; rather, it changes the experience of the first year following transplantation.

It is the clinicians and the transplant team’s duty to find the “best donor” at the “right time.” The hematologists, transplant doctors, advanced practitioners, pharmacists, nurses, and coordinators have the burden of the entire puzzle of donor selection. Practically speaking, this requires balancing the optimal match against donor availability, donor suitability, and the urgency of the disease process. Clinicians need to factor in the role of the donor type in determining the conditioning regimen, GVHD prophylaxis strategy (which includes the use of PTCy and other drugs), and relapse/infection surveillance.So,all the healthcare team members cab be effected by this mechanism.

Both payers and policymakers are stakeholders, as the type of donor has an influence on cost trends. The initial transplant hospitalization cost is not the whole story. Additional expenses occur when complications result in re-hospitalizations, extended immunosuppression, costly interventions, or the ongoing treatment of GVHD. Initiatives that facilitate rapid donor recruitment, swift authorization, and utilization of expert centers could minimize complications and save time.

Families and donors are also affected. In most cases, a sibling donor assumes the challenging position of a donor suddenly, with associated medical assessments, logistics, and personal involvement. Most donors are healthy, yet donation is a medical procedure that comes with potential risks. It is essential for centers to emphasize donor safety, informed consent, and donor follow-up in situations where donors have to travel, take time off work, or provide care for their dependents.

Equity and access considerations**

“Best donor access” is not distributed equally and will influence who gets access to transplant at the optimal time. Counseling can be essential for patients who require assistance in finding the best donor, getting approved by insurance companies, arranging travel to transplant centers, and making plans for care-giving arrangements. In situations where there is no matching donor from the patient’s own family, proper counseling becomes crucial when deciding between several potential donors.

What Changes**

• When a matched sibling donor is identified, that donor is always the preferred choice by transplant teams as it is always going to be the surest path to successful transplant using the PTCy regimen. The use of sibling donors reduces the risk of having adverse reactions from GVHD, allows easier immune recovery, and also saves time without compromising on compatibility.
• PTCy may continue to make more compatible donors available for patients lacking a matched sibling, but it does not eliminate the inherent benefits that come with a sibling match. Transplants performed using haploidentical or unrelated donors can also yield positive results, and the use of PTCy has certainly allowed more patients to undergo transplants than before. However, the donor type affects patient care even in terms of infections and other chronic complications.
• In planning health system resources, consideration should be made based on the source of the donations. This entails adopting flexible staffing options, infection control processes, procedures for evaluating GVHD, as well as survival management procedures which would be ready to cater for chronic GVHD in case it happens. Donor transplant centers should ensure there are facilities for patient education and care-giving training as well as management of out-patient complications.
• To enhance patient outcomes, policy makers and payers should promote equitable access and reduce delays in the whole process. It requires having strong donor registries, donor supply, authorization, and accessibility to centers that perform transplantations. Patients may have to be transplanted in their correct disease windows, and in case no match sibling exists, donors should be found in time and delays prevented. References Tiercy J-M. How to select the best available related or unrelated donor of hematopoietic stem cells? Haematologica. 2016;101(6):680–687. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5013969 Ido K, Nakamae H. Donor selection for allogeneic hematopoietic cell transplantation in the posttransplant cyclophosphamide era. International Journal of Hematology. 2026. Available from: https://link.springer.com/article/10.1007/s12185-026-04202-5 Fuji S, Ohmoto A. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis: current status and optimization strategies. Current Opinion in Immunology. 2025;97:102662. Available from: https://pubmed.ncbi.nlm.nih.gov/40974838 Meybodi MA, Cao W, Luznik L, Bashey A, Zhang X, Romee R, et al. HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Advances. 2019;3(17):2581–2585. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6737418